Date post: | 05-Jan-2016 |
Category: |
Documents |
Upload: | rachel-wells |
View: | 214 times |
Download: | 0 times |
Mahatma Gandhi Cancer Hospital and Research Institute
Dr P. S. Bhattacharyya, MDRadiation Oncologist.
Elekta Synergy
CT Simulator
Flexitron HDR
Computed tomography assisted High Dose Rate Interstitial Brachytherapy in Gynaecologic Malignancies,
with Inverse Planning Simulated Annealing ; An Institutional experience.
Author-Dr P S Bhattacharyya, MD Co-author-Mr A C prabhu, Med. Phy.
Introduction
Ca. Cx - 40% of all cases treated at MGCH EBRT + CDDP 40 mg/m ICRT / IBT GEC Estro guidelines for 3D ICRT MUPIT
2
Aims of the study
To report IPSA based 3D HDR IBT in cancer Cervix and Vagina
DVH analysis of CTV and OAR
Materials and Methods
May 2012 to Dec 2012 Retrospective analysis 34 IBT applications in 17, Ca.Cx / Vagina patients Duration < 3 hrs Median 19 (17-23) needles used 8 – 9.5 Gy X 2 prescibed dose IPSA
Clinical and Histopathological features PRESENTATIONBleeding P/VWhite dischargePelvic Pain
NO. OF PATIENTS 14 12 06
PERCENTAGE 82 70 35
HPESq. Cell Ca.Adeno Ca.
16 01
94 06
SITEIntact CervixVaultVagina
10 05 02
59 29 12
FIGO STAGE IIBIIIBIIIB with L/3 Vagina involved
07 10 03
41 59 30
Total patients studied-17 Median age -56 Yrs.(18-68 yr)
Perineal Template Indications
Bad Geometry 47% (08) Ca. Vault area 29% (05) Vaginal and para vaginal involvement 12% (02) Non negotiable cervical OS 06% (01) ICRT high dose to bladder 06% (01)
Total No. of patients studied-17
Interstitial applicators
Vienna CT-MRI Ring/ Ovoid Applicator
Syed Neblett Template
MUPIT Applicator
BED and DEQ Equations
BEDExt+HDR= (nd[1+(---)]) + (nd[1+(---)])
DEQ = BEDExt+HDR
d d
d ref 1+ ( ---- )
n = no. Of fractionsd = dose per fraction in Gya/b = alpha / beta, 10 for tumor, 3 for late effects
BED=biologically equivalent doseDEq= Equivalent dose (Gy)d ref= reference dose, 2 Gy
a/b a/b
a/b
IPSA Planning
CTV DVH Interpretations
CTV Range Median BED 10Tumor effects
Dose Eq.Gy
D100 4.87 – 8.49 Gy 5.82 Gy
D95 7.26 – 9.17 Gy 8.42 Gy 84.08 70.06
D90 8.14– 9.60 Gy 8.74 Gy 85.80 71.50
V100 85 – 96.77 % 91.13%
Median Prescribed dose- 8.8 Gy
OAR DVH Interpretation
BladderVolume cc
RangeGy
Median dose Gy
BED 3Late effects
Dose Eq.Gy
0.1 6.25-9.85
8.01 130 78.31
1 5.52-7.90
6.75 115.87 69.80
2 4.98-7.13
6.29 110.95 66.84
5 3.82-6.47
5.63 105.36 63.47
Rectal Volume cc
RangeGy
Median dose Gy
BED 3Late effects
Dose Eq.Gy
0.1 6.47-8.49
7.36 122 73.49
1 5.70-7.27
6.49 113.06 68.11
2 5.30-6.01
6.02 108.20 65.18
5 4.23-6.46
5.40 102 61.44
URINARY BLADDER RECTUM
Median Prescribed Dose- 8.8 Gy
IPSA isodose distribution
Comparision of bladder dose
0.1 cc bladder dose 12 Gy with ICRT 0.1 cc bladder dose 8.1 Gy with IBT
Limitations of the study
All the patients did not recieve 6 cycles of CDDP Total duration of treatment more than 8 weeks Applicator volume in CTV No subdivisions in CTV
Thank you